Helping Children Receive an Earlier Autism Diagnosis

For Parents For Providers

Earlier Diagnosis + Earlier Intervention = Better Outcomes

CLICK HERE to read our latest publication in the journal of Autism Research (June 18, 2020)

The NPDX ASD blood test is a new diagnostic tool that may lead to an earlier diagnosis for children with autism spectrum disorder (ASD).

About Our Autism Blood Test

Our blood test is validated by our National Institutes of Mental Health clinical study, the largest study to evaluate the metabolism of children with autism.

How Our Test Was Validated

The results of our clinical study were published in the peer-reviewed scientific journals Biological Psychiatry and Autism Research.

The Science Behind Our Test

We improve the lives of children and families living with autism spectrum disorder by providing tools for earlier diagnosis and more precise treatment.

Our Mission and Leadership

Earlier access to specialty care and treatments improve outcomes

Talk to your healthcare Provider (pediatrician, family doctor) about requesting our test for your child.

Talking to Your Provider

Print the NeuroPointDX brochure which summarizes our company and our autism test for your Provider.

The NPDX ASD Brochure

Sign-up to receive updates on our progress developing tools for autism diagnosis and treatment.

Sign-Up for Newsletters

Publications

NeuroPointDX, through its parent company Stemina Biomarker Discovery, has published papers in peer-reviewed journals and presented research at meetings around the world.

A Metabolomics Approach to Screening for Autism Risk in the Children’s Autism Metabolome Project – Autism Research article

Smith AM, Natowicz MR, Braas D, Ludwig MA, Ney DM, Donley ELR, Burrier RE, Amaral DG ABSTRACT Autism spectrum disorder (ASD) is biologically and behaviorally heterogeneous. Delayed diagnosis of ASD is common and problematic. The complexity of ASD and the low sensitivity of available screening tools are key factors in delayed diagnosis. Identification of biomarkers[...]

Posters

NeuroPointDX, through its parent company Stemina Biomarker Discovery, has published papers in peer-reviewed journals and presented research at meetings around the world.

Identification of Neurotransmitter-Associated and Other Metabotypes: Further Stratification of the Children’s Autism Metabolome Project (CAMP) ASD Subjects

Presented at the 2019 Annual Meeting of the International Society for Autism Research (INSAR) in Montreal, Ontario, Canada in May 2019. The Children’s Autism Metabolome Project (CAMP), ClinicalTrials.gov: NCT02548442, recruited 1,100 children for metabolomic analyses to identify altered metabolism associated with ASD. Previous research identified ASD subjects associated with branched-chain amino acid (BCAA) dysregulation. With this[…]

NeuroPointDX Names Two Senior Diagnostics Industry Executives to the Board of Directors

NeuroPointDX, a division of Stemina Biomarker Discovery, today announced the appointment of two new board members with extensive experience in the development and commercialization of new molecular diagnostic tests. Barbara Handelin, PhD, was founding Director of the DNA Diagnostics Lab at Integrated Genetics (acquired by LabCorp @ $925M), and Tony Shuber was Chief Technology Officer[...]